DIAGENS

Executive Summary

DIAGENS is a privately held Chinese diagnostics company specializing in molecular diagnostic tests for infectious disease and oncology. Founded in 2010 and based in Shanghai, the company has grown to 200-500 employees and reached the commercial stage, indicating it already has products on the market. Its focus on early detection and monitoring addresses critical unmet needs in China's healthcare system, leveraging advanced technologies for accurate and rapid testing. While specific financials are not disclosed, the company's established commercial presence suggests a stable revenue base. However, competition in the Chinese diagnostics market is intense, and DIAGENS must continue innovating to maintain its position. The company's conviction score is 65, reflecting its commercial maturity but limited public visibility and uncertain differentiation.

Upcoming Catalysts (preview)

• Q3 2026NMPA approval for a novel oncology liquid biopsy test70% success
• Q2 2026Expansion of infectious disease test menu through strategic partnership60% success
• Q4 2025Launch of a point-of-care molecular diagnostic platform for rural hospitals50% success